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Abstract To analyze risk factors for ischemic stroke and
transient ischemic attack (TIA) in young adults under the
age of 50. To make recommendations for additional
research and practical consequences. From 97 patients with
ischemic stroke or TIA under the age of 50, classical car-
diovascular risk factors, coagulation disorders, history of
migraine, use of oral contraceptives, cardiac abnormalities
on ECG and echocardiography, and the results of duplex
ultrasound were retrospectively analyzed. Literature was
reviewed and compared to the results. 56.4% of the patients
had hypertension, 12.1% increased total cholesterol, 20%
hypertriglyceridemia, 31.5% an increased LDL-level,
32.6% a decreased HDL-level and 7.2% a disturbed glucose
tolerance. Thrombophilia investigation was abnormal in 21
patients and auto-immune serology was abnormal in 15
patients. Ten of these patients were already known with a
systemic disease associated with an increased risk for
ischemic stroke (i.e. systemic lupus erythematosus). The
ECG was abnormal in 16.7% of the cases, the echocardi-
ography in 12.1% and duplex ultrasound of the carotid
arteries was in 31.8% of the cases abnormal. Conventional
cardiovascular risk factors are not only important in patients
over the age of 50 with ischemic stroke or TIA, but also in
this younger population under the age of 50. Thrombophilia
investigation and/ or autoimmune serology should be
restrictedtopatientswithoutconventionalcardiovascularrisk
factors and a history or other clinical symptoms associated
with hypercoagulability and/ or autoimmune diseases.
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Introduction
Stroke is the most important cause of disablement in the
western world. In the Netherlands it is the third cause of lost
Disability-Adjusted Life-Years (DALY’s)––after coronary
disease and anxiety diseases [1]. About 10% of all strokes
occur in patients \50 years of age. Risk factors in these
youngstrokepatientsdifferfromthosefoundinolderpeople
[2]. Etiology of ischemic stroke in young adults remains
uncertain [3, 4] and multiple factors have been reported as
risk factors like traditional vascular risk factors [5, 6],
thrombophilia [6–18], migraine [6, 19–22], auto-immune
disorders [23–27] and cardiac anomalies [6, 28–35].
Thepresent studyaimed to determine classical riskfactors
andprevalenceofthrombophilicriskfactorsandautoimmune
serology in patients under the age of 50 with transient ische-
micattack(TIA)orischemicstroke.Furthermorethepractical
consequences of these investigations are discussed.
Patients and methods
Population
This retrospective study included a series of 97 patients
under the age of 50, diagnosed with ischemic stroke or TIA
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DOI 10.1007/s11239-010-0491-3(after history taking, physical examination and brain
imaging studies), admitted to the neurology department of
the Radboud University Nijmegen Medical Centre between
September 2004 and January 2008. Medical records of
these patients were reviewed. The data of these patients
were retrospectively analyzed and compared with
literature.
Risk factors
The following data were collected: gender, age, type of
event, smoking, use of oral contraceptives, cardiovascular
history (previous stroke or TIA, myocardial infarction,
venous thromboembolism, hypertension, hypercholester-
olemia or pre-eclampsia/HELLP-syndrome/spontaneous
abortion), positive family history for cardiovascular disease
(ﬁrst-degree female family members \65 years and ﬁrst-
degree male family members \55 years), migraine, dia-
betes, blood pressure (hypertension was classiﬁed as a
blood pressure [140/90 mmHg or treatment with antihy-
pertensive medication) ECG, echocardiography and duplex
ultrasound of the extra cranial arteries.
Cardiac imaging
ECGs were analyzed. Almost all patients underwent two-
dimensional transthoracic echocardiography (TTE).
Potential cardiac sources of embolism were: patent fora-
men ovale (PFO), atrial septal aneurysm (ASA), mitral
stenosis, mitral insufﬁciency, atrial ﬁbrillation, endured
myocardial infarction, endocarditis, intracardial thrombus,
atrial myxoma, prosthetic valve, non-ischemic dilating
cardiomyopathy and left ventricular akinesis.
Carotid ultrasound
The results of duplex ultrasound of the extra cranial arteries
were divided in four categories: normal, non-signiﬁcant
atherosclerotic changes (e.g. slightly increased intima
media thickness without signiﬁcant haemodynamic chan-
ges), signiﬁcant atherosclerotic changes (i.e. vascular ste-
nosis with luminal reduction C50%) and other signiﬁcant
vascular damage (i.e. dissection).
Laboratory assays
The following laboratory data were evaluated: total cho-
lesterol, triglycerides, LDL cholesterol, HDL cholesterol,
glucose, protein C, free protein S and antithrombin activity,
factor V Leiden, factor II mutation (prothrombin
G202010A mutation), homocysteine, lupus anticoagulant
and anticardiolipin antibodies (IgG and IgM), antinuclear
antibodies (ANA), anti-neutrophil cytoplasmic antibodies
(ANCA).
Reference values were 70–150% for protein C,
65–130% and 55–115% respectively for men and women
for free protein S,[80% for antithrombin,\15 lmol/l for
homocysteine, \6.5 mmol/l for total cholesterol, \2.00
mmol/l for triglycerides, [1.10 mmol/l for HDL and
\3.50 mmol/l for LDL cholesterol. The normal values for
fasting blood sugar and non-fasting blood sugar were\6.1
and\7.8 mmol/l.
Results
Cardiovascular risk factors
Of the 97 patients, 49 had an ischemic stroke and 48 had a
TIA. Mean age of the study population was 41.3 ± 7.7
years (range 17.04–49.97 years) and 57 (58.8%) were
females. The presence of the classical atherosclerotic risk
factors are presented in Table 1. The most common car-
diovascular risk factor was hypertension (56.4%), followed
by a positive cardiovascular medical history (47.9%),
a positive family history (44.4%) and smoking (40.0%).
32.6% of the patients had a decreased HDL-level. LDL was
elevated in 31.5%. 73.2% of the patients had two or more
cardiovascular risk factors. Only 8.5% had no cardiovas-
cular risk factor.
Cardiac imaging
ECGs showed hardly any abnormalities (Table 2). Dis-
turbed repolarisation was the most common abnormality
(7.7%). In our population ﬁve patients had a PFO (6.4%)
and also ﬁve patients (6.4%) had mitral insufﬁciency
(Table 2). One patient had a congenital anomaly consisting
of a pulmonary artery aplasia and hypoplastic right
ventricle.
Gynaecological history
14% (8) of the women had a history of one or two spon-
taneous abortions. Three of them had a history of pre-
eclampsia. 42.9% of the women used oral contraceptives
(Table 1).
Migraine
In our study group, 20.2% of the patients had a history of
migraine. The combination of migraine and the use of oral
contraception occurred in 9.3%, the combination of
migraine and PFO in 3.1%. Sixty percentage of the patients
with PFO were familiar with migraine.
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123Carotid ultrasound
The results of the duplex ultrasound are shown in Table 2.
20% of the patients had non-signiﬁcant and 11.8% had
signiﬁcant atherosclerotic changes or dissection.
Thrombophilic and autoimmune investigations
Not all patients had a complete trombophilia and auto-
immune work-up (Table 2). Increased homocysteine was
present in 13.6%. The two patients with mildly decreased
protein C and the patient with decreased protein S used oral
contraceptives. The auto-immune research resulted in a
positive ANA in 8.1% and a positive ANCA in 7.4%.
Studying the history of the patients, we found that a dis-
order associated with increased blood coagulation and/or
vasculitis in combination with ischemic stroke was present
in 17 patients (Table 3). This group represented 1/2
decreased protein C, 1/1 decreased antithrombin, 1/1
positive lupus anticoagulant, 3/6 FVL, 1/3 factor II muta-
tion, 5/7 positive ANA and 2/6 positive ANCA (divided
over 10 patients). Two patients in Table 2 were not
screened for trombophilia and auto-immune disorders.
Some patients showed more than one abnormality. One
patient known with SLE had a positive ANA and lupus anti-
coagulant;onepatientwithSLEpresentedwithpositiveANA,
FVLandfactorIImutation;onepatientknownwithM.Crohn
had a decreased protein C and antithrombin; a patient with
Table 1 Demographic data and risk factors
All (n = 97) Males Females
Nonmodiﬁable risk factors
Age, y 41.3 ± 7.7 (17.04–49.97)
a 43.0 ± 7.2 (17.04–49.97)
a 40.1 ± 7.8 (19.25–49.89)
a
Gender – 40 (41.2) 57 (58.8)
Ischemic stroke (N) 49 (50.5) 19 (38.8) 30 (61.2)
TIA (N) 48 (49.5) 21 (43.8) 27 (56.2)
Number scored (%) Positive result (%)
Cardiovascular family history – 90 (92.8) 40 (44.4)
Well-documented and modiﬁable risk factors
Cardiovascular history – 94 (96.9) 45 (47.9)
Cigarette smoking – 95 (97.9) 38 (40)
Hypertension – 94 (96.9) 53 (56.4)
Hypercholesterolemia – 91 (93.8) 11 (12.1)
Hypertriglyceridemia – 90 (92.8) 18 (20.0)
Increased LDL – 89 (91.8) 28 (31.5)
Decreased HDL – 89 (91.8) 29 (32.6)
Glucose[7.8 – 97 (100) 7 (7.2)
Glucose[6.1 – 97 (100) 19 (19.6)
Cardiovascular risk factors
b –––
0 – 82 (84.5) 7 (8.5)
1 – 82 (84.5) 15 (18.3)
2 – 82 (84.5) 21 (25.6)
3 – 82 (84.5) 16 (19.5)
4 – 82 (84.5) 14 (17.1)
5 – 82 (84.5) 8 (9.8)
6 – 82(84.5) 1 (1.2)
Less well-documented, potentially modiﬁable risk factors
History of migraine – 94 (96.9) 19 (20.2)
Oral contraceptive use – 96 (99.0)/56 (98.2) 24 (25.0)/24 (42.9)
Data are expressed as mean ± SD or n(%)
TIA transient ischemic attack; LDL low-density lipoprotein; HDL high-density lipoprotein
a Range
b Smoking, hypertension, high glucose level, high total cholesterol, high triglycerides, high LDL, low HDL, signiﬁcant changes of duplex
ultrasound, positive cardiovascular history
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123decreased protein C and FVL had a history of pre-eclampsia
and two spontaneous abortions; one patient with a blank his-
tory showed a positive ANA and anticardiolipin IgG.
None of the patients with a coagulation disorder had a
PFO.
Discussion
The results of the present study demonstrate that conven-
tional cardiovascular risk factors are not only an important
riskfactorinpatientsovertheageof50withischemicstroke/
TIA, but also in this younger population under the age of 50.
Almost half of the patients (47.9%) had a positive car-
diovascular history. Eight of these patients had a history of
spontaneous abortions and/or pre-eclampsia. Also the
family history for cardiovascular disease was frequently
positive (44.4%). In the Netherlands, 28% of the general
population was smoking at that time [36], in our population
40% was smoking. The results of the lipids and glucose
values are difﬁcult to compare with results from the liter-
ature because of different cut-off values.
58.8% of our population was of the female gender. This
is comparable with the literature [37]. The higher propor-
tion of women is possibly due to the nature of risk factors
for stroke/TIA at younger age; like pregnancy, migraine en
oral contraceptives use. These risk factors tend to occur
more frequently in women.
We found a history of migraine in 20.2% of the popu-
lation. This is analogous to the results of Milhaud et al.
[19]. They found migraine in 29.3% of their population,
which was younger (\35 years). Furthermore they found
18.2% of the patients with migraine (\45 years) having a
PFO. This is analogous to our results (15.8%). Of all
women in our study 42.9% used oral contraceptives. This is
comparable to the Dutch population between 20 and
45 years old (41%) [38].
In contrast to what is known from literature, a small
number of cardiac anomalies was detected by echocardi-
ography. Kittner [3] and Rodes-Cabau et al. [33] described
cardiogenic emboli as the most common cause of ischemic
stroke in younger persons (15.4%). PFO and atrial septal
aneuryms (ASA) are described in literature as the most
common cardiac anomaly found in stroke/TIA [28–32].
Cabanes et al. [28] distinguished PFO in 43% and ASA in
28% of the population \55 years old. In our study PFO
was detected in only 6.4% and ASA in 1.3% of the patients.
This discrepancy can be explained by the difference in
technique of echocardiography. Cabanes et al. [28] used––
like most of the other investigators [29–32]––transesoph-
ageal echocardiography (TEE), instead of TTE. It is sug-
gested that the transesophageal technique is more sensitive
in detecting interatrial septum anomalies (PFO, ASA, atrial
septal defect), atrial thrombi during atrial ﬁbrillation and
mitral valve vegetations like endocarditis [35].
Most of the abnormalities found in thrombophilia- and
auto-immune investigations, were detected in patients
already known with diseases associated with an increased
coagulation before the stroke occurred. Furthermore all
patients with decreased protein C and S used oral contra-
ception, which is a known cause of decreased protein C and
S[ 18].
Hankey et al. [8] demonstrated no signiﬁcant differences
between patients with young stroke and controls for protein
Table 2 Etiology of ischemic stroke/TIA
Positive result (%)
Echocardiography (n = 78)
PFO 5 (6.4)
ASA 1 (1.3)
Mitralis stenosis 0
Mitralis insufﬁcience 5 (6.4)
Atrial ﬁbrilation 0
Endured myocardial infarction 2 (2.6)
Endocarditis 0
Intracardial thrombus 0
Atrial myxoma 0
Prosthetic valve 2 (2.6)
Non-ischemic dilating cardiomyopathy 1 (1.3)
Left ventricular akinesis 2 (2.6)
Congenital cardiac anomaly 1 (1.3)
ECG (n = 91) –
Sinus rhythm 91 (100)
Atrial ﬁbrillation 0
Endured myocardial infarction 0
Disturbed repolarisation 7 (7.7)
Left ventricle hypertrophy 1 (1.1)
Left bundle-branch block 1 (1.1)
Congenital cardiac anomaly 2 (2.2)
Thrombophilia –
Protein C\70 (n = 82) 2 (2.4)
Free Protein S: #\65; $\55 (n = 82) 1 (1.2)
Antithrombin\80 (n = 85) 1 (1.2)
Factor V Leiden
a (n = 85) 6 (7.1)
Factor II mutation
a (n = 84) 3 (3.6)
Homocysteine[15 (n = 81) 11 (13.6)
Auto-immune –
Lupus anticoagulant (n = 85) 1 (1.2)
Anticardiolipine IgG (n = 83) 2 (2.4)
Anticardiolipine IgM (n = 83) 1 (1.2)
ANA (n = 86) 7 (8.1)
ANCA (n = 81) 6 (7.4)
PFO patent foramen ovale, ASA atrial septal aneurysm;
a Heterozygote
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123C, S and antithrombin levels. Amiri et al. [9] did not ﬁnd
decreased levels of protein C and antithrombin at all. The
percentages of protein C and S that Hankey et al detected
are in the range with the percentages we found, except for
the antithrombin level. We found a decreased antithrombin
level in only 1.2% of the patients compared to 5.2% of
Amiri et al.
The percentage of our patients with FVL and factor II
mutations (7.1 and 3.6%) is in accordance with the results
of the literature [8, 10, 14–16]; none of these studies
reported signiﬁcant differences between patients and con-
trols, or just a minimal increased risk. It has to be noted
that positive trombophilia screening has no practical con-
sequences for the patient. There is no difference in kind
and duration of anticoagulant treatment between patients
with or without a thrombophilic factor.
The homocysteine level was increased in 11 patients.
Nowadays it is questionable whether it is still useful to
investigate homocysteine levels, since large placebo-con-
trolled trials are published concerning the effect of treating
hyperhomocysteinemia [39–42]. Patients (with hyperhom-
ocysteinemia) in these studies had a positive vascular his-
tory or a myocardial infarction. Vitamin supplementation
caused no signiﬁcant decrease of recurrence hazard of
cardiovascular events. Only Saposnik et al. [43] concluded
that vitamin supplementation reduces the risk of overall
stroke (ischemic and haemorrhagic), but not stroke severity
or disability in a population with and without history of
cerebrovascular disease.
In our population a few patients with positive anti-
phospholipid antibodies were found (1.2%). Brey et al. [24]
found a prevalence of 26.9% of antiphospholipid antibod-
ies and a prevalence of 14% of anticardiolipin IgG and
0.6% of anticardiolipin IgM. Difference with our popula-
tion is the fact they only measured all antibodies once,
without the corroboration of a second measurement. The
patients in our population had a positive test result
repeatedly. Munts et al. [2] found a conﬁrmed prevalence
of anticardiolipin IgG of 17%. Nencini et al. [25] found
prevalences of 18, 9 and 7% for antiphospholipid anti-
bodies, anticardiolipin IgG and IgM.
Urbanus et al. [26] found lupus anticoagulant to be a
signiﬁcant risk factor (OR 43.1) for arterial thrombotic
event in women under age 50. Antiphospholipid antibodies
were present in 17% of the patients. The APASS investi-
gators [27] concluded that the presence of antiphospholipid
antibodies does not predict an increased risk for subsequent
vascular occlusive events in patients with a non-cardio-
genic stroke. And thereby may not offer enough value for
decisions on therapy.
In contrast to the literature [29, 30] we did not identify a
combination of thrombophilia and PFO in our population.
This can be caused by a low prevalence of both parameters
in our population. Furthermore the size of our population is
too small to demonstrate an association. Belvı ´s[ 31] and
Florez et al. [34] did not ﬁnd a signiﬁcant association
between patients with and without PFO for coagulation
disorders.
A limitation of this study is that it is retrospective,
resulting in incomplete data. Strength of the study is that
we investigated many possible risk factors for ischemic
stroke in one study. Many studies investigated just one or
Table 3 Disorders associated with increased blood coagulation/vasculitis
n Comment
Systemic lupus erythematosus 2 1 with positive ANA and lupus anticoagulant; one with positive ANA,
FVL and factor II mutation
Colitis ulcerosa 2 1 with positive ANA; one with positive ANCA
M. Crohn 2 1 with FVL; one with decreased PC and AT
Systemic malignancy 2 1 with Non-Hodgkin lymphoma; one with Hodgkin lymphoma
Rheumatoid arthritis 1 Positive ANA
Syndrome of Sneddon 1 Positive ANCA
Moya Moya syndrome 1
Henoch-Scho ¨nlein 1
Discoid lupus erythematosus 1
M. Buerger 1 FVL
Anti-Jo-1-antibodies syndrome 1 Positive ANA
Thrombotic thrombocytopenic purpura 1
a
Polycythaemia vera 1
a
Total n(% of total patient population) 17 (17.5%)
ANA anti-nuclear antibodies, FVL factor V Leiden, ANCA anti-neutrophil cytoplasmic antibodies, PC protein C, AT antithrombin
a Two patients were not screened for thrombophilia and auto-immune disorders
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123few risk factors in relation to ischemic stroke. Additional
prospective, controlled studies of ischemic stroke/TIA
patients under age 50 are needed to better assess the roles
of the risk factors in the etiology of ischemic stroke/TIA. A
relation between migraine and stroke should be corrobo-
rated by further studies.
Conclusion and recommendations
Screening for conventional cardiovascular risk factors
remains the most important considering the high percent-
age of cardiovascular risk factors in patients under age 50.
These high frequencies also indicate optimal secondary
prevention strategies.
Based on the low laboratory yield of thrombophilia- and
auto-immune search, it is not indicated to do this complete
laboratory search in all patients under 50, especially not
when there is no history related to these diseases. Fur-
thermore in most cases a positive thrombophilic factor has
no therapeutic consequences, such as switching of type of
anticoagulation or duration of anticoagulation. Thrombo-
philia and auto-immune research is only indicated in spe-
ciﬁc cases.
Because of the low number of abnormalities found in
TTE, TEE seems preferable instead. Disadvantage of the
transesophageal technique is its more invasive nature.
Another possibility is the use of TEE in selected young
patients, without other risk factors for ischemic stroke.
The ECG should be used to exclude atrial ﬁbrillation. It
is cheap and simple.
The use of duplex ultrasound of the extra cranial arteries
should be continued. It is a non-invasive test and gives
information about the presence of atherosclerosis or dis-
section in the carotid arteries. Is has a sensitivity of 86%
and speciﬁcity of 87% [44].
History taking remains important in detecting risk fac-
tors. Characteristics of auto-immune diseases could be
speciﬁcally interrogated.
The recommendation for diagnostic testing for possible
etiologies and risk factors of ischemic stroke or transient
ischemic attack in patients under age 50 is summarized in
Fig. 1. The suggested scheme developed on the basis of the
results of this study should be further validated in pro-
spective studies.
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